12:01 PM EST - ProMIS Neurosciences, Inc. : Announced today that the journal Neurology will publish AAN abstracts of data that demonstrate the strength of its antibody programs for Parkinson’s disease/alpha-synuclein (a-syn) and amyotrophic lateral sclerosis (ALS)/TDP-43. The data will appear in the April 14 online supplement to Neurology, the most widely read, highly cited peer-reviewed neurology journal. ProMIS Neurosciences, Inc.
shares T.PMN are trading down $0.005 at $0.13.
